MAH0 Stock Chart & Stats
€0.23
>-€0.01(-1.52%)
At close: 4:00 PM EDT
€0.23
>-€0.01(-1.52%)
Day’s Range― - ―
52-Week Range€0.20 - €1.95
Previous CloseN/A
Volume0.00
Average Volume (3M)326.00
Market Cap
€39.29M
Enterprise Value€21.97M
Total Cash (Recent Filing)€30.12M
Total Debt (Recent Filing)€1.03M
Price to Earnings (P/E)―
Beta<0.01
Next Earnings
Nov 17, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.18
Shares Outstanding159,690,980
10 Day Avg. Volume0
30 Day Avg. Volume326
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)1.62
Price to Sales (P/S)132.86
P/FCF Ratio-2.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€2.69Price Target Upside1067.59% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)-0.06
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageMinimal debt limits solvency pressure and preserves financial flexibility relative to more highly leveraged biotech peers. This gives Mereo greater capacity to direct capital toward clinical development and partnerships, although it does not eliminate the need for future funding.
Capital-light Partnership EconomicsThe Sentynl agreement creates potential non-dilutive funding and future royalty economics while sharing commercialization responsibilities. This partnership-based model can reduce the capital burden of advancing alvelestat and provide meaningful upside if clinical and regulatory milestones are achieved.
Rare-disease Pipeline FocusA focus on oncology and rare diseases targets areas with significant unmet medical needs, where differentiated therapies may support partnering interest and commercial access. Advancing multiple candidates also gives Mereo more than one potential path to create value over time.
Bears Say
Near-zero Revenue And Persistent LossesThe absence of meaningful current revenue leaves Mereo dependent on future clinical success, licensing proceeds, or external financing rather than operating income. Persistent large losses reduce financial resilience and make the business model highly sensitive to development outcomes and funding access.
Continued Cash BurnMaterially negative operating and free cash flow shows that Mereo is not currently self-funding its operations. Continued cash consumption increases reliance on capital raising or partnership proceeds, potentially constraining development plans and creating ongoing liquidity and financing risk.
Listing Compliance RiskFailure to restore Nasdaq bid-price compliance could threaten the company’s listing and reduce access to global biotech investors. A delisting would likely complicate financing, trading liquidity, and market visibility during a period when Mereo already needs external funding.
Mereo Biopharma Group Plc News
MAH0 FAQ
What was Mereo Biopharma Group Plc’s price range in the past 12 months?
Mereo Biopharma Group Plc lowest stock price was €0.20 and its highest was €1.95 in the past 12 months.
What is Mereo Biopharma Group Plc’s market cap?
Mereo Biopharma Group Plc’s market cap is €39.29M.
When is Mereo Biopharma Group Plc’s upcoming earnings report date?
Mereo Biopharma Group Plc’s upcoming earnings report date is Nov 17, 2026 which is in 21 days.
How were Mereo Biopharma Group Plc’s earnings last quarter?
Mereo Biopharma Group Plc released its earnings results on Aug 11, 2026. The company reported -€0.009 earnings per share for the quarter, missing the consensus estimate of -€0.007 by -€0.002.
Is Mereo Biopharma Group Plc overvalued?
According to Wall Street analysts Mereo Biopharma Group Plc’s price is currently Undervalued.
Does Mereo Biopharma Group Plc pay dividends?
Mereo Biopharma Group Plc does not currently pay dividends.
What is Mereo Biopharma Group Plc’s EPS estimate?
Mereo Biopharma Group Plc’s EPS estimate is -0.01.
How many shares outstanding does Mereo Biopharma Group Plc have?
Mereo Biopharma Group Plc has 159,690,980 shares outstanding.
What happened to Mereo Biopharma Group Plc’s price movement after its last earnings report?
Mereo Biopharma Group Plc reported an EPS of -€0.009 in its last earnings report, missing expectations of -€0.007. Following the earnings report the stock price went up 38.983%.
Which hedge fund is a major shareholder of Mereo Biopharma Group Plc?
Currently, no hedge funds are holding shares in DE:MAH0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mereo Biopharma Group Plc Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€2.69 (1067.59% Upside)
€2.69 (1067.59% Upside)
Blogger Sentiment
Bullish
DE:MAH0 Sentiment 100%
Sector Average 67%
Sector Average 67%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-86.25%
12-Months-Change
Fundamentals
Return on Equity
-74.76%
Trailing 12-Months
Asset Growth
-44.57%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Mereo Biopharma Group Plc
Mereo BioPharma Group plc, a London-based biopharmaceutical firm established in 2015, specializes in developing and commercializing innovative therapies for oncology and rare conditions. Operating both in the United Kingdom and internationally, the company boasts a diverse product pipeline. Its primary oncology asset, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor, is presently undergoing Phase 1b clinical investigation for tumor treatment. Another cancer compound, Navicixizumab (OMP-305B83), has already concluded its Phase 1b clinical studies for patients battling late-stage ovarian cancer. Beyond cancer, Mereo is advancing several other promising candidates. These include Acumapimod (BCT-197), a p38 MAP kinase inhibitor, which is currently in Phase II clinical trials for addressing acute exacerbations of chronic obstructive pulmonary disease. Additionally, Leflutrozole (BGS-649), an oral aromatase inhibitor, is being developed to manage hypogonadotropic hypogonadism. Within its rare disease portfolio, Mereo features Setrusumab (BPS-804), a novel antibody designed to treat osteogenesis imperfecta, and Alvelestat (MPH-966), an oral small molecule in Phase II clinical trials for Alpha-1 antitrypsin deficiency. To bolster its research, Mereo BioPharma collaborates with The University of Texas MD Anderson Cancer Center, focusing on the evaluation of its anti-TIGIT therapeutic antibody candidate, etigilimab.
MAH0 Stock 12 Month Forecast
Average Price Target
€2.69
▲(1067.59% Upside)